Recruiting
Asthma
RecruitingStudy of Three Doses of Frevecitinib (KN-002) in Adults with Severe Asthma Not Controlled by Medium‑to‑High Dose Inhaled Steroid/LABA Therapy
Registered drug
Study of Three Doses of Frevecitinib (KN-002) in Adults with Severe Asthma Not Controlled by Medium‑to‑High Dose Inhaled Steroid/LABA Therapy
Registered drug
- Disease:Asthma
- Substances:Salbutamol Sulfate
Countries:
Bulgaria
Bulgaria- Participants:18–64 years · 65+ years
- Substances:Salbutamol Sulfate
- Sponsor:Kinaset Therapeutics Inc.
